10-K: Immunic Secures $187M, Advances MS & Celiac Programs

Immunic, Inc. announced a significant private placement raising $187 million, extending its operational runway while progressing its lead multiple sclerosis and celiac disease drug candidates through clinical trials and securing key intellectual property.

Summary

• Immunic, Inc. is a late-stage biotechnology company focused on novel oral therapies for neurologic and gastrointestinal diseases, with main operations in Germany and headquarters in New York City.
• The company reported a net loss of $97.2 million for the year ended December 31, 2025, an improvement from $100.5 million in 2024.
• Accumulated deficit reached approximately $608.6 million as of December 31, 2025.
• Cash and cash equivalents were $15.5 million as of December 31, 2025, but a subsequent private placement in February 2026 raised approximately $187.0 million in net cash, expected to fund operations beyond 12 months.
• The lead drug candidate, vidofludimus calcium (IMU-838), is in Phase 3 clinical development for Relapsing Multiple Sclerosis (RMS), with enrollment completed for both ENSURE-1 and ENSURE-2 trials (total 2,221 patients). Top-line data is expected by the end of 2026.
• A positive interim analysis of the ENSURE program in October 2024 confirmed futility criteria were not met, recommending continuation without sample size increase.
• Phase 2 CALLIPER trial of vidofludimus calcium in Progressive Multiple Sclerosis (PMS) showed substantial reductions in 24-week confirmed disability progression (24wCDW) and statistically significant 24-week confirmed disability improvement (24wCDI), along with reduced thalamic brain volume loss.
• Long-term open-label extension (OLE) data from the Phase 2 EMPhASIS trial in RRMS demonstrated favorable safety and tolerability for up to 5.5 years, with low discontinuation rates (6.4% annualized).
• IMU-856, for gastrointestinal diseases like celiac disease, showed positive effects in a Phase 1b trial, including protection of gut architecture, symptom improvement, biomarker response, and enhanced nutrient absorption. It also demonstrated a dose-dependent increase of GLP-1 levels and reduced body weight gain in preclinical testing.
• The IMU-381 program, leveraging the Nurr1 platform for neurologic, gastrointestinal, and other autoimmune diseases, is currently in preclinical testing.
• A Notice of Allowance was received from the USPTO in September 2025 for a patent protecting vidofludimus calcium's dose strengths in PMS, extending protection into 2041.
• The company transferred its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market in January 2026 due to non-compliance with the $1.00 minimum bid price rule, receiving an extension until June 22, 2026.
• A preliminary proxy statement was filed on February 20, 2026, to seek stockholder approval for a reverse stock split at a ratio of not less than 10:1 to regain Nasdaq compliance and increase authorized shares.
• A Royalty Purchase Agreement was entered into on February 12, 2026, where 51,087,000 Series B Warrants were exchanged for a 5% synthetic royalty on future sales of the vidofludimus calcium program.
• Research and development expenses increased slightly to $82.0 million in 2025 from $80.0 million in 2024, primarily due to increased external development costs for vidofludimus calcium and personnel expenses, partially offset by decreased IMU-856 development costs.
• General and administrative expenses increased to $21.2 million in 2025 from $18.0 million in 2024, mainly due to personnel, legal, and consultancy expenses.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing. The substantial capital raise significantly de-risks near-term liquidity concerns and provides runway for critical clinical programs. Positive clinical data for IMU-838 in MS and IMU-856 in celiac disease, coupled with IP protection, are strong indicators of pipeline progress. However, the Nasdaq delisting risk and the need for a reverse stock split, along with continued operating losses, temper the overall sentiment.

Positives

• Successfully completed enrollment for both Phase 3 ENSURE trials (ENSURE-1 with 1,121 patients, ENSURE-2 with 1,100 patients) for vidofludimus calcium in RMS.
• Positive outcome from an interim futility analysis of the Phase 3 ENSURE program in October 2024, recommending continuation without changes.
• Phase 2 CALLIPER trial in PMS showed substantial and medically relevant reductions in 24-week confirmed disability progression (24wCDW) and statistically significant 24-week confirmed disability improvement (24wCDI).
• CALLIPER data also indicated reductions in the annualized rate of thalamic brain volume loss and volume of new or enlarging T2 lesions in PMS patients.
• Vidofludimus calcium demonstrated a favorable safety and tolerability profile across multiple clinical trials, including long-term OLE data from the Phase 2 EMPhASIS trial (up to 5.5 years treatment duration, 6.4% annualized discontinuation rate).
• Received a Notice of Allowance from the USPTO in September 2025 for a patent covering vidofludimus calcium's dose strengths in PMS, providing protection into 2041.
• IMU-856 Phase 1b clinical trial in celiac disease patients showed positive effects in gut architecture protection, symptom improvement, biomarker response, and nutrient absorption.
• IMU-856 demonstrated a highly statistically significant (p=0.014 for 80mg, p=0.003 for 160mg) and dose-dependent increase of endogenous GLP-1 levels in celiac disease patients.
• A private placement closed on February 17, 2026, raising approximately $187.0 million in net cash, extending the company's operational funding beyond twelve months.
• Received $4.8 million in grant income from the German Federal Ministry of Finance in 2025 for research activities.

Negatives

• Incurred a net loss of $97.2 million in 2025 and an accumulated deficit of $608.6 million as of December 31, 2025.
• The company has never been profitable and does not anticipate paying cash dividends in the foreseeable future.
• Non-compliance with Nasdaq Listing Rule 5450(a)(1) (minimum $1.00 bid price) led to transfer to the Nasdaq Capital Market and a delisting risk if compliance is not regained by June 22, 2026.
• Requires stockholder approval for a reverse stock split (ratio not less than 10:1) to address Nasdaq compliance and increase authorized shares, with no guarantee of approval.
• The second and third tranches of the January 2024 Financing, which could have provided an additional $160 million, were not exercised and expired on October 31, 2025.
• The company's clinical trials were delayed and costs increased due to the ongoing military action in Ukraine, with approximately 35 active sites in western Ukraine still at risk.
• The Phase 2 clinical trial of vidofludimus calcium in moderate-to-severe ulcerative colitis did not achieve its primary endpoint, leading to no further development plans in this indication without a partner.

Risks

• Failure to obtain additional financing on acceptable terms could force delays, reductions, or termination of development programs or commercialization efforts.
• Additional financings may be dilutive to existing stockholders and may impose significant restrictions on operations.
• Macroeconomic conditions, including inflation, higher interest rates, supply chain disruptions, and geopolitical conflicts (e.g., Russia-Ukraine war), could adversely affect business and clinical development timelines.
• Clinical development is lengthy, expensive, and uncertain; clinical failure can occur at any stage, and earlier results may not predict later outcomes.
• Product candidates may cause undesirable adverse effects, delaying or preventing regulatory approval, limiting labeling, or resulting in negative consequences post-approval.
• The regulatory approval process is lengthy, time-consuming, and inherently unpredictable, with no guarantee of obtaining or maintaining marketing approval.
• Commercial success depends on market acceptance, ability to build sales and marketing capabilities, third-party coverage and reimbursement, and effective competition.
• Significant competition from major pharmaceutical and biotechnology companies with greater resources and experience.
• The potential market size for product candidates may be smaller than estimated if assumptions are inaccurate.
• Inability to attract and retain key management and scientific personnel could hinder successful development or commercialization.
• Uncertainty in protecting and enforcing intellectual property rights could impair competitive position.
• Failure to meet Nasdaq continued listing requirements, including the $1.00 minimum bid price, could result in delisting.
• The market price of common stock has been and may continue to be volatile.
• Anti-takeover provisions in organizational documents and Delaware law might discourage or delay acquisition attempts.
• Future sales and issuances of common stock or rights to purchase common stock could result in additional dilution.
• Potential liability from product liability claims, especially if uninsured or exceeding coverage.
• Risk of misconduct or improper activities by employees, contractors, or collaborators, including noncompliance with regulatory standards and insider trading.
• Difficulties in managing organizational growth could disrupt operations.
• Internal computer systems or those of third parties may fail or suffer security breaches, disrupting product development.
• Evolving SEC rules and other legal requirements regarding cybersecurity incident reporting and disclosure could result in regulatory scrutiny and increased costs.
• Negative developments in the field of oral therapies for chronic inflammatory and autoimmune diseases could damage public perception.
• Price controls may be imposed in foreign markets, adversely affecting future profitability.
• Reliance on third-party suppliers and manufacturers for product candidates exposes the company to production delays, manufacturing defects, and compliance risks.
• Inability to realize potential benefits from collaborations if partners do not commit sufficient resources or if disagreements arise.
• Failure to obtain patent term extension in the U.S. and foreign countries could shorten market exclusivity.
• Incorrect interpretation of third-party patents could lead to infringement liability or costly licenses.
• Non-compliance with governmental patent agency requirements could reduce or eliminate patent protection.
• Patent protection may expire before commercial value is maximized, leading to increased competition.
• Lawsuits or interference proceedings to protect intellectual property rights could be expensive and unsuccessful.
• Third-party claims of intellectual property infringement or misappropriation could prevent development or commercialization.
• Changes in U.S. patent law could diminish the value of patents.
• Confidentiality agreements may not adequately prevent disclosure of trade secrets.
• Need to license certain intellectual property from third parties, which may not be available on reasonable terms.
• Claims that employees, consultants, or contractors have wrongfully used or disclosed confidential information of third parties.
• Claims challenging the inventorship or ownership of patents and other intellectual property.
• Reliance on third parties requires sharing trade secrets, increasing risk of discovery or misappropriation.
• Inadequate protection of trademarks and trade names could hinder name recognition.
• Significant costs and demands on management from complying with public company laws and regulations.
• Failure to maintain proper and effective internal controls could impair accurate financial statements.
• Limitations on the ability to use net operating loss carryforwards and other tax attributes to offset future taxable income.

Future Outlook

The company expects to incur significant and increasing operating losses for the foreseeable future as it continues clinical development, prepares for potential commercialization of vidofludimus calcium, and expands its pipeline. Top-line data for the Phase 3 ENSURE trials in RMS is expected by the end of 2026. Further clinical testing of IMU-856 is being prepared, contingent on financing, licensing, or partnering. The company is also exploring options for certain assets and technologies, including a potential spin-off and licensing transactions. A search for a new CEO with deep commercial expertise in the MS space is underway, with the current CEO transitioning to a scientific strategy role.

Management Comments

• "We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms."
• "We believe that vidofludimus calcium, with combined neuroprotective, anti-inflammatory, and antiviral effects as well as a favorable safety and tolerability profile, has the potential to be a unique treatment option targeted to the complex pathophysiology of MS."
• "We believe that the combined mechanisms of vidofludimus calcium are unique in the MS space and support the therapeutic performance observed in our Phase 2 EMPhASIS trial in RRMS patients and in our Phase 2 CALLIPER trial in PMS patients."
• "We believe this compound [IMU-856] may represent a unique treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function and bowel wall architecture in patients suffering from gastrointestinal diseases."
• "We believe that, since 24wCDW is an accepted regulatory endpoint to demonstrate clinical benefit in PMS, this evidence of clinical activity merits further investigation and de-risks a potential Phase 3 program."
• "We believe that this data set [IMU-856 Phase 1b] provided initial clinical proof-of-concept for an entirely new therapeutic approach to gastrointestinal disorders by promoting regeneration of bowel architecture."
• "We believe that this [IMU-856 GLP-1 effects] should be further evaluated in future clinical development."
• "We believe that this Phase 3 program [ENSURE] should provide a straightforward path towards potential regulatory approval of vidofludimus calcium in RMS."
• "We believe that this feedback [from FDA on CALLIPER] provides a clear path forward for starting a confirmatory program for vidofludimus calcium in PMS populations."
• "We expect to continue to lead most of our research and development activities from our Gräfelfing, Germany location... we anticipate that this should result in more timely and cost-effective execution of our development programs."
• "Our Co-Founder and Chief Executive Officer, Dr. Daniel Vitt, and the Board will begin a search for a new CEO with deep commercial expertise in the MS space to lead Immunic through its next stage of growth and into commercialization."

Industry Context

StockSavvy.ai notes that Immunic operates in highly competitive therapeutic areas, particularly Multiple Sclerosis and gastrointestinal diseases. The positive Phase 2 data for vidofludimus calcium in PMS and long-term safety in RRMS, coupled with its unique Nurr1 activation and DHODH inhibition mechanisms, position it as a potentially differentiated oral therapy in the crowded MS market, especially given the challenges faced by other BTKi candidates like Evobrutinib and Tolebrutinib. The focus on neuroprotection and antiviral effects, particularly against EBV, addresses emerging understanding of MS pathophysiology. For celiac disease, IMU-856's mechanism targeting intestinal barrier regeneration is a novel approach compared to existing anti-inflammatory treatments, potentially offering a significant advantage in a market with high unmet needs beyond a gluten-free diet. The recent capital raise provides crucial runway, a common challenge for clinical-stage biotechs, but the Nasdaq delisting risk highlights ongoing market perception and valuation pressures.

Comparison to Industry Standards

• Vidofludimus calcium's consistent 24wCDW results across PMS patient populations and subgroups, including those without baseline inflammatory Gd+ lesions, are notable, as current anti-inflammatory therapies often show no utility in non-active SPMS where disease progression is driven by smoldering disease rather than focal inflammation.
• The over two-fold probability for 24wCDI with vidofludimus calcium over placebo in the overall PMS population is statistically significant and compares favorably to the limited treatment options available for progressive MS, such as Ocrevus (ocrelizumab) which is approved specifically for PPMS, and other drugs like siponimod which showed limited effect in non-active SPMS.
• The favorable safety and tolerability profile of vidofludimus calcium, with low discontinuation rates and no new safety signals observed over up to 5.5 years in RRMS patients, differentiates it from some traditional immunomodulators that carry risks like PML (e.g., natalizumab, ocrelizumab, dimethyl fumarate, fingolimod). Teriflunomide, another DHODH inhibitor, has also shown a lack of PML cases, suggesting a potential class-wide differentiator.
• The observed neuroprotective effects and Nurr1 activation mechanism of vidofludimus calcium address a key unmet need in MS, as current disease-modifying therapies (DMTs) often lack significant efficacy against progression independent of relapse activity (PIRA) and smoldering neurodegeneration.
• IMU-856's mechanism of action, targeting the restoration of intestinal barrier function and bowel wall architecture, represents a unique approach in celiac disease, where current treatments are limited to a strict gluten-free diet and many patients still experience symptoms. This mechanism could offer an advantage over immunosuppressive medications by maintaining immune surveillance.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation that it believes would materially affect its business, operating results, financial condition, or cash flows.
• The industry is characterized by frequent claims and litigation, including securities litigation, patent and intellectual property rights claims, and product liability claims, indicating potential future involvement in legal proceedings.

Related Party Transactions

• On December 29, 2025, Duane Nash, Executive Chairman, entered into an employment agreement to serve as Chief Executive Officer and President of Gliomic Therapeutics Inc., a wholly-owned subsidiary, effective January 1, 2026. This agreement outlines his salary, benefits, and termination provisions.
• The Royalty Purchase Agreement on February 12, 2026, involved certain Series B Warrant holders (Participating Series B Holders) and BVF Partners, L.P. (BVF) acting as royalty interest agent, exchanging warrants for a 5% synthetic royalty on future sales of the vidofludimus calcium program. Thor Nagel, an Analyst with BVF, was appointed to the Board of Directors on the same day.

Stakeholder Impact

• **Shareholders:** The recent $187 million capital raise provides significant funding, reducing immediate liquidity concerns and supporting ongoing clinical programs. However, the Nasdaq delisting risk and the need for a reverse stock split could negatively impact share price and liquidity. Future equity raises could lead to further dilution. The exchange of Series B Warrants for a royalty interest could be seen as a way to retain investor interest while managing warrant overhang.
• **Employees:** The company had 92 employees as of February 1, 2026, with 68 in R&D, indicating a strong focus on product development. The CEO transition and search for a new CEO with commercial expertise could bring new strategic direction and opportunities, but also potential uncertainty.
• **Customers (Future):** Successful clinical trial outcomes for vidofludimus calcium and IMU-856 could lead to new treatment options for patients with MS and celiac disease, addressing significant unmet medical needs.
• **Creditors:** The improved cash position from the recent private placement enhances the company's ability to meet its financial obligations and fund operations, reducing credit risk.
• **Partners/Collaborators:** The company continues to rely on third-party CROs and manufacturers, and is evaluating strategic collaborations, indicating ongoing relationships and potential for new partnerships to advance its pipeline.

Next Steps

• Public announcement of top-line data from Phase 3 ENSURE trials (ENSURE-1 and ENSURE-2) by the end of 2026.
• Determine appropriate next steps for vidofludimus calcium in PMS, following Phase 2 CALLIPER trial results and feedback from healthcare authorities, including starting a confirmatory Phase 3 program.
• Prepare for additional clinical testing of IMU-856, contingent on financing, licensing, or partnering.
• Continue preclinical research for the IMU-381 program and explore additional indications for potential future development.
• Facilitate readiness for potential commercial launch of product candidates, if regulatory approvals are received, through targeted pre-commercial activities.
• Evaluate potential strategic collaborations for each product candidate.
• File a resale registration statement on Form S-3 (or S-1) for the February 2026 Offering investors within 45 days of the February 17, 2026 closing date.
• Seek stockholder approval for an amendment to the certificate of incorporation to effect a reverse stock split (ratio not less than 10:1) at a special meeting, following the preliminary proxy statement filed on February 20, 2026.
• Continue efforts to regain compliance with Nasdaq's $1.00 minimum bid price rule by June 22, 2026.
• Begin a search for a new CEO with deep commercial expertise in the MS space.
• Dr. Daniel Vitt plans to transition to a new senior executive role focused on strengthening scientific strategy and driving portfolio advancement.

Key Dates

Recommendation

The company has made significant progress with its clinical pipeline, particularly with positive Phase 2 data for vidofludimus calcium in PMS and IMU-856 in celiac disease, and the completion of enrollment for Phase 3 RMS trials. The recent $187 million capital raise is a crucial positive, providing necessary funding for operations beyond the next 12 months. However, the company remains pre-revenue with a substantial accumulated deficit and faces immediate challenges such as Nasdaq delisting risk and the need for a reverse stock split. The CEO transition also introduces an element of uncertainty. While the long-term potential of its drug candidates is promising, the current risks and the need for further clinical and regulatory milestones suggest a 'hold' recommendation for seasoned investors, awaiting clearer outcomes from the Phase 3 trials and resolution of listing issues before considering a more aggressive stance.

Keywords

Biotechnology, Multiple Sclerosis, Celiac Disease, IMU-838, Vidofludimus Calcium, IMU-856, Clinical Trials, Phase 3, Neuroprotective, Anti-inflammatory, Autoimmune Diseases, Gastrointestinal Diseases, Nasdaq Delisting, Reverse Stock Split, Capital Raise, Drug Development, Nurr1, DHODH Inhibitor, Biopharma, SEC Filing